← The patent line

Benzoyl Peroxide

Sold as EPSOLAY · given by topical

Ten years or more until it comes off patent
14.8 yr
Until anyone may copy it
Protection runs to 2041-05-23
10
Trials running now
227 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Mayne Pharma Llc
Approval holder
the only company permitted to sell it today
2041-05
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Acne VulgarisAcneSurgical Site Infection
03

Who is paying for the research

Galderma R&D
Company
4
Inova Health Care Services
University or hospital
3
GlaxoSmithKline
Company
3

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07639073In routine use2026 · 164 people · not yet recruiting
Low-Dose Versus Conventional-Dose Oral Isotr

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line